Guanfacine, a medication commonly prescribed to alleviate symptoms of post-traumatic stress disorder, is no more effective than a placebo, according to a study led by researchers at the San Francisco VA Medical Center.
The 2006 American College of Neuropsychopharmacology annual meeting will feature hundreds of new studies on brain and behavior from the world’s leading scientists. Presentations include innovative research on potential new treatments for Alzheimer’s disease, autism, nicotine addiction and treatment resistant depression.
Novartis unveiled today new data on its promising pipeline amid plans for multiple new product approvals and launches over the next two years. Many of these anticipated approvals are for potentially best-in-class medicines that would advance treatment standards for patients with hypertension, diabetes, cancer and other diseases.
The turbidity of red wine during its ageing in oak casks has an influence on the accumulation of volatile compounds and, thereby, on the wine’s aroma, but not on the accumulation of biogenic amines. This is the conclusion of Nerea Jim?nez Moreno in her PhD thesis defended at the Public University of Navarre.
A new study shows that blood flow to the legs is relatively normal in people with diastolic heart failure, suggesting other potential causes of their inability to do everyday activities, according to researchers at Wake Forest University Baptist Medical Center.
King Pharmaceuticals, Inc. (NYSE: KG) and Depomed, Inc. (NASDAQ: DEPO) today announced the launch of a new program that will provide support for patients with diabetes who are receiving treatment with Glumetza (metformin hydrochloride extended-release tablets), a new once-daily extended-release metformin formulation that features AcuForm drug-delivery technology.
Seventy-six percent of workers older than 60 years of age are overweight or obese. However, less than one third of those 40 years of age and younger suffer these health issues. This is one of the conclusions shown in the research of Alberto Cordero of the School of Medicine, and the University Hospital.
Compounds known to play an important role in how insects develop from larvae to adults have been shown in a mouse model for congestive heart failure to be effective in preventing and reducing cardiac cell overgrowth and irregular heart rhythms, according to UC Davis research published in the early online edition of the Proceedings of the National Academy of Sciences.
An enzyme inhibitor that regulates insect larvae development reduces heart enlargement and irregular heart rhythms in a mouse model, a 16-member University of California, Davis research team has discovered. The work, published in the current edition of Proceedings of the National Academy of Sciences, could lead to important new medications to treat human heart patients.
News tips from the 2006 annual meeting of the American Society of Nephrology, Nov. 14 to 19, San Diego.